Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Clinics; 73 (supl.1), 2018
Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most w...
Carcinoma Epitelial de Ovario/epidemiología, Carcinoma Epitelial de Ovario/genética, Mutación de Línea Germinal, Recombinación Homóloga/genética, Pérdida de Heterocigocidad, Neoplasias Ováricas/epidemiología, Neoplasias Ováricas/genética, Poli(ADP-Ribosa) Polimerasa-1, Inhibidores de Poli(ADP-Ribosa) Polimerasas, Poli(ADP-Ribosa) Polimerasas/uso terapéutico, Análisis de Secuencia